Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing
العنوان: | Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing |
---|---|
المؤلفون: | Xiang Li, Yang Liu, Wei-Chao Dou, Shangqing Ren, Kan Wu, Thongher Lia, Xu Hu, Yao-Hui Wang, Shuyang Feng, Kang Wu, Wei-Xiao Yang, Zhen Yang, Yan-Xiang Shao, San-Chao Xiong |
المصدر: | Cancer Cell International Cancer Cell International, Vol 21, Iss 1, Pp 1-10 (2021) |
بيانات النشر: | Springer Science and Business Media LLC, 2021. |
سنة النشر: | 2021 |
مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, DNA damage, Population, DNA damage response and repair, medicine.disease_cause, lcsh:RC254-282, DNA sequencing, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Genetics, medicine, lcsh:QH573-671, education, Gene, 030304 developmental biology, 0303 health sciences, Mutation, education.field_of_study, Bladder cancer, lcsh:Cytology, business.industry, Hazard ratio, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Predictive model, 030220 oncology & carcinogenesis, Next-generation sequencing, Bacillus Calmette–Guérin, Primary Research, business, Epirubicin, medicine.drug |
الوصف: | Objective To investigate the genetic prognostic factors for the recurrence of non-muscle invasive bladder cancer. Materials and methods The patients underwent transurethral resection of bladder tumor and received bacillus Calmette–Guérin (BCG) or epirubicin. Next-generation sequencing was performed and alterations of genes, pathways, and tumor mutation burden were recorded. Associations between these clinicopathological and genetic variants were estimated, and prognostic factor identified. Results A total of 58 cases were included in our study, and 46 patients underwent treatment with BCG. FGFR3 was the most frequently altered gene (48%), and more commonly detected in intermediate-risk patients. Univariate Cox analysis demonstrated that 10 genes were significantly correlated with BCG failure, while NEB, FGFR1 and SDHC were independent recurrence predictors. Besides, epigenetic-related gene pathway mutations were negatively correlated with recurrence (hazard ratio: 0.198, P = 0.023). DNA damage response and repair gene alterations were positively correlated with tumor burden, while altered TP53 was most frequent among these genes and significant correlated with high tumor burden. Conclusion BCG instillation significantly reduced the rate of recurrence compared with epirubicin in this population. Potential biomarkers and therapeutic targets were found with the help of next-generation sequencing; correlations between DDR genes alterations and high tumor mutation burden were also demonstrated. |
تدمد: | 1475-2867 |
URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5f88d92583f87d79cf416889ddffbd https://doi.org/10.1186/s12935-020-01731-9 |
حقوق: | OPEN |
رقم الأكسشن: | edsair.doi.dedup.....ba5f88d92583f87d79cf416889ddffbd |
قاعدة البيانات: | OpenAIRE |
تدمد: | 14752867 |
---|